☆ 4.6 Review

Mesenchymal Chondrosarcoma from Diagnosis to Clinical Trials

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Mesenchymal chondrosarcoma: An Australian multi-centre cohort study

Madeleine C. Strach et al.

Summary: This study evaluates prognostic factors, treatments, and outcomes of mesenchymal chondrosarcoma (MCS) in an Australian setting. Results showed that patients with localized disease who underwent surgical resection had improved overall survival. Understanding treatment patterns and outcomes is important for treatment decisions and novel therapeutic strategies.

CANCER MEDICINE (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex

Jialin Mo et al.

Summary: The study identifies SSRP1 as a crucial gene that is directly induced by EWSR1::FLI1 and forms an oncogenic positive feedback loop with it, promoting EwS oncogenesis. The FACT inhibitor CBL0137 effectively disrupts this loop, providing a novel therapeutic strategy for treating EwS.

ONCOGENE (2023)

添加到收藏夹

Review Oncology

Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials

Shigeto Nishikawa et al.

Summary: Mutations in the tumor suppressor p53 occur in about 50% of human cancers, leading to impaired tumor suppressive function and oncogenic activities of mutant p53. Various approaches, including restoration of wild-type p53 conformation, rescue of p53 nonsense mutations, depletion of mutant p53 proteins, and induction of p53 synthetic lethality or targeting of vulnerabilities imposed by p53 mutations, have been used to target p53 mutations in the development of cancer therapies. This review article summarizes the mechanisms of action and activities of clinically available FDA-approved drugs and drugs in clinical trials that target p53 mutations for suppressing cancer progression.

CANCERS (2023)

添加到收藏夹

Review Medicine, General & Internal

Chondrosarcoma: A Clinical Review

Aaron Gazendam et al.

Summary: Chondrosarcomas are malignant cartilaginous matrix-producing tumors, with a spectrum of biologic activity ranging from low-grade to high-grade tumors. Diagnosis, treatment, and prognosis vary based on the histologic grade of the tumor. Distinguishing between high-grade and intermediate-grade chondrosarcomas, as well as low-grade tumors and benign enchondromas, poses a diagnostic challenge. A multidisciplinary team at a tertiary sarcoma center provides optimal care for these patients.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Review Oncology

Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions

Antoine Gilbert et al.

Summary: This review article describes the origins of chondrosarcoma radiation-resistance and proposes potential solutions to improve treatment based on tumor grade and characteristics. Chondrosarcoma, a chemoresistant and radioresistant tumor, is difficult to treat with surgery due to its location. The resistance is attributed to the composition of the tumor, which creates a low oxygen tension microenvironment causing the cells to dedifferentiate into cancer stem cells. Hadrontherapy, with its ballistic properties and greater biological effectiveness, combined with targeted inhibitors, is considered a promising option for treating high-grade chondrosarcoma.

CANCERS (2023)

添加到收藏夹

Review Oncology

Classification of Chondrosarcoma: From Characteristic to Challenging Imaging Findings

Jun-Ho Kim et al.

Summary: Chondrosarcomas are a diverse group of cartilage-forming tumors that make up a significant portion of malignant bone tumors. They are classified as benign, intermediate, or malignant based on their histopathological features. Distinguishing between enchondromas and low-grade chondrosarcomas, as well as between low-grade and high-grade chondrosarcomas, is challenging. Various advanced imaging modalities can aid in the diagnosis, and a multidisciplinary approach is necessary for treatment decisions.

CANCERS (2023)

添加到收藏夹

Article Medicine, Research & Experimental

HEY1-NCOA2 expression modulates chondrogenic differentiation and induces mesenchymal chondrosarcoma in mice

Miwa Tanaka et al.

Summary: This study aimed to clarify the functional role of HEY1-NCOA2 in the development and progression of mesenchymal chondrosarcoma. They found that introducing HEY1-NCOA2 into mouse embryonic cells successfully induced subcutaneous tumors with biphasic morphologies and the expression of chondrogenic differentiation marker Sox9. The interaction between HEY1-NCOA2 and Runx2 was observed, and treatment with the HDAC inhibitor panobinostat suppressed tumor growth both in vitro and in vivo.

JCI INSIGHT (2023)

添加到收藏夹

Article

Spinal mesenchymal chondrosarcoma: A case report of a rare malignant tumor

Younes Dehneh et al.

Surgical Neurology International (2023)

添加到收藏夹

Article

Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas

Georgina E. Wood et al.

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting (2023)

添加到收藏夹

Review Oncology

Systemic Therapy for Chondrosarcoma

Adam Rock et al.

Summary: Clinical trial enrollment should be actively encouraged in all patients diagnosed with advanced, surgically unresectable chondrosarcoma (CS) due to the lack of consensus treatment recommendations. Treatment options for CS vary depending on histologic subtype and targetable mutations. Conventional CS is resistant to cytotoxic chemotherapy, but antiangiogenic therapy and IDH1 inhibitors may be beneficial. Alternative options include mTOR inhibitors or other tyrosine kinase inhibitors, although sequencing data is lacking. Treatment for dedifferentiated CS involves chemotherapies, but immunotherapy with pembrolizumab or ivosidenib in IDH1-mutant, dedifferentiated CS has questionable efficacy. Mesenchymal CS may be treated with Ewing sarcoma-like chemotherapy regimens, but data supporting its use is limited.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)

添加到收藏夹

Review Clinical Neurology

Primary intra- and extradural extramedullary mesenchymal chondrosarcoma with isolated punctate calcification: case report and literature review

Meigui Chen et al.

Summary: We present a case of intraspinal dumbbell-shaped mesenchymal chondrosarcoma (MCS) in a 19-year-old male with lower back pain. Surgical removal of the tumor was performed and postoperative pathology confirmed MCS. CT and MRI are important for differential diagnosis of intraspinal MCS, especially when there is homogeneous enhancement and punctate calcification. Despite a good prognosis, close follow-up after surgery is necessary.

BMC NEUROLOGY (2022)

添加到收藏夹

Article Oncology

Genomic profiling identifies genes and pathways dysregulated by HEY1-NCOA2 fusion and shines a light on mesenchymal chondrosarcoma tumorigenesis

Wenqing Qi et al.

Summary: Mesenchymal chondrosarcoma is a rare and aggressive primitive mesenchymal tumor that mainly affects adolescents and young adults. Researchers have identified the fusion protein HEY1-NCOA2, which promotes cell proliferation and upregulates the expression of PDGFB and PDGFRA, providing a potential target for treating mesenchymal chondrosarcoma.

JOURNAL OF PATHOLOGY (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal

Extraskeletal Mesenchymal Chondrosarcoma of the Uterus

Yurimi Lee et al.

Summary: Mesenchymal chondrosarcoma is a rare malignant tumor with aggressive behavior. We present a rare case of uterine mesenchymal chondrosarcoma and describe its histological and immunophenotypical features. This will help in accurate diagnosis and treatment of the disease.

DIAGNOSTICS (2022)

添加到收藏夹

Article Oncology

Mesenchymal chondrosarcoma of the head and neck with HEY1::NCOA2 fusion: A clinicopathologic and molecular study of 13 cases with emphasis on diagnostic pitfalls

Bin Xu et al.

Summary: This study analyzed 13 molecularly confirmed cases of head and neck mesenchymal chondrosarcoma (MCS) and found that it can occur intraosseously or extraosseously, and has a longer survival compared to MCS in other sites. Testing for specific gene fusions is recommended in head and neck tumors with specific morphological features and lack of distinct cartilaginous components.

GENES CHROMOSOMES & CANCER (2022)

添加到收藏夹

Article Oncology

Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report

Veronika Blum et al.

Summary: This article presents a case of a patient with metastatic osseous spread of mesenchymal chondrosarcoma, who showed sustained clinical improvement and good partial response on imaging during one year of treatment with the multi-tyrosine kinase inhibitor cabozantinib. Tumors with similar genetic patterns may respond to the same therapy.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Retroperitoneal mesenchymal chondrosarcoma with metastasis to iliac vein: A rare case report and review of the literature

Mahsa Masjedi Esfahani et al.

Summary: In this study, we reviewed a rare case of retroperitoneal mesenchymal chondrosarcoma with initial metastasis to the iliac bone, further progressing to involve the iliac vein. This case contributes to the understanding of the characteristics of ESMC.

CLINICAL CASE REPORTS (2022)

添加到收藏夹

Review Oncology

CT and MRI findings of intracranial extraskeletal mesenchymal chondrosarcoma-a case report and literature review

Jixiang Chu et al.

Summary: This article presents a case of intracranial extraskeletal mesenchymal chondrosarcoma (EMCS) and focuses on its imaging characteristics. The importance of identifying the imaging features is highlighted, as it can aid in the differential diagnosis and clinical decision-making.

TRANSLATIONAL CANCER RESEARCH (2022)

添加到收藏夹

Review Oncology

Primary mesenchymal chondrosarcoma of the adult lumbar spine: a case report and review of the literature

Maoqiang Lin et al.

Summary: PMC is a rare malignancy that can be effectively treated with total tumor resection. It is essential to increase awareness of this disease in the clinic.

TRANSLATIONAL CANCER RESEARCH (2022)

添加到收藏夹

Review Oncology

Rare malignant primary spinal intradural extramedullary mesenchymal chondrosarcoma: a case report and literature review

Yunda Wang et al.

Summary: Mesenchymal chondrosarcoma (MCS) is a rare malignant tumor with a high risk of recurrence and distant metastasis, often originating in bone tissue. This article reports a rare case of spinal intradural extramedullary MCS with herpes virus infection, the first such case reported in East China. The patient presented with symptoms such as low-grade fever, sweating, progressive constipation, weakness in lower extremities, and hypoesthesia, but after surgical resection and chemotherapy, no evidence of tumor recurrence or distant metastasis was found at the 1-year follow-up.

TRANSLATIONAL CANCER RESEARCH (2022)

添加到收藏夹

Article Medicine, General & Internal

A Rare Case Report of Mesenchymal Chondrosarcoma with Pancreatic Metastasis

Jian-Jiun Chen et al.

Summary: Mesenchymal chondrosarcoma is a rare and aggressive subtype of sarcoma, primarily affecting the axial skeleton but occasionally involving extra-skeletal soft tissues or organs. Active surveillance with multidisciplinary team management can significantly prolong the survival outcomes of patients.

MEDICINA-LITHUANIA (2022)

添加到收藏夹

Article Orthopedics

Effect of surgery and radiotherapy on overall survival in patients with chondrosarcoma: A SEER-based study

Miao Wang et al.

Summary: Surgical resection is the key treatment for chondrosarcoma, and radiotherapy does not provide significant advantage in improving patient survival time.

JOURNAL OF ORTHOPAEDIC SURGERY (2022)

添加到收藏夹

Review Oncology

Mesenchymal chondrosarcoma of the chest wall in an adolescent patient: A case report and brief review of the literature

Marti Goldenberg et al.

Summary: The case presents a 17-year-old male with back pain and a posterior mediastinal mass, eventually diagnosed with mesenchymal chondrosarcoma. Despite multiple resections for local recurrence, the patient declined adjuvant chemotherapy and elected for hospice care.

CANCER REPORTS (2022)

添加到收藏夹

Article Cell Biology

NKX3.1 immunoreactivity is not identified in mesenchymal chondrosarcoma: a 25-case cohort study

Wei Chen et al.

Summary: This study aimed to evaluate the potential diagnostic utility of NKX3.1 immunohistochemistry in mesenchymal chondrosarcoma (MC), but no immunoreactivity was found in all 25 cases. The negativity of NKX3.1 immunoreactivity could not be explained by the clonality of the antibody.

HISTOPATHOLOGY (2021)

添加到收藏夹

Article Orthopedics

Mesenchymal chondrosarcoma: imaging features and clinical findings

Soleen Ghafoor et al.

Summary: Primary mesenchymal chondrosarcoma typically presents as aggressive lytic bone lesions with chondroid calcifications. Approximately one-third of cases exhibit a biphasic morphology. Metastases are common at initial presentation, especially with larger tumors.

SKELETAL RADIOLOGY (2021)

添加到收藏夹

Review Oncology

MEK inhibitors for the treatment of non-small cell lung cancer

Jing Han et al.

Summary: BRAF and KRAS mutations play a significant role in NSCLC by activating the RAS/RAF/MEK/ERK signaling pathway. Current approved therapies include BRAF and MEK inhibitors, while combination with other drugs may enhance therapeutic effects. Further research is needed to explore optimal drug combinations for treating lung cancer patients.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Proton Radiation Therapy for Pediatric Skull Base Chondrosarcomas

M. Ioakeim-Ioannidou et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Article Pathology

NKX3.1 a useful marker for mesenchymal chondrosarcoma: An immunohistochemical study

Madiha Syed et al.

Summary: The study aimed to explore the utility of NKX3.1 as a diagnostic marker of mesenchymal chondrosarcoma. NKX3.1 immunohistochemistry was applied to 21 cases of mesenchymal chondrosarcoma and 32 cases of other round blue cell tumors. Results showed that 66.7% of mesenchymal chondrosarcoma cases stained positive for NKX3.1, while all other round blue cell tumors were negative, suggesting NKX3.1 as a useful immunohistochemical marker in distinguishing mesenchymal chondrosarcoma from its histological mimics.

ANNALS OF DIAGNOSTIC PATHOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action

Pawel Lukasik et al.

Summary: Recent studies have shown that small molecule drugs targeting CDK inhibitors have become attractive options for treating cancer and neurodegenerative disorders. Most CDK inhibitors target the ATP binding pocket, but the similarity in structure among CDK kinases makes achieving selectivity challenging. Therefore, inhibitors binding outside the ATP binding site have attracted great interest for their potential applications in the biomedical field.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Health Care Sciences & Services

Rare case report and literature review of intracranial mesenchymal chondrosarcoma

Li-Yang Fu et al.

Summary: Intracranial mesenchymal chondrosarcoma is a rare primary malignant tumor in the skull, often originating from abnormal residual chondrocytes in the embryonic period. It is difficult to diagnose and easily misdiagnosed, requiring differentiation from other intracranial masses. Surgical intervention and combined radiotherapy and chemotherapy are the main treatment options, with a focus on accurate diagnosis and appropriate management strategies.

ANNALS OF PALLIATIVE MEDICINE (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

Chao Dong et al.

Summary: Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression in breast cancer patients. Current research is focusing on developing drugs targeting this pathway to overcome acquired resistance to standard therapies.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Review Oncology

Chondrosarcoma-from Molecular Pathology to Novel Therapies

Agnieszka E. Zajac et al.

Summary: Chondrosarcoma (CHS) is the second most common primary malignant bone sarcoma, with a challenging treatment and surgery as the main approach. This review provides a multidisciplinary characterization of CHS from its pathology to therapies, including subtype morphology, immunohistochemical markers, frequently mutated genes, and altered pathways. The discussion also covers ongoing clinical trials of targeted therapies, which may serve as potential future targets for designing new therapeutics.

CANCERS (2021)

添加到收藏夹

Article Oncology

Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma

Warren Chow et al.

CANCER (2020)

添加到收藏夹

Article Orthopedics

Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis

Kamil M. Amer et al.

JOURNAL OF ORTHOPAEDIC RESEARCH (2020)

添加到收藏夹

Article Pathology

NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma

Ken-ichi Yoshida et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)

添加到收藏夹

Letter Ophthalmology

Primary intraocular mesenchymal chondrosarcoma: a histopathological surprise in an enucleated eye

Ratnesh Ranjan et al.

CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE (2020)

添加到收藏夹

Article Clinical Neurology

OLIG2 Immunolabeling of Mesenchymal Chondrosarcoma: Report of 14 Cases

Kun Yao et al.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2020)

添加到收藏夹

Article Oncology

Long lasting response with trabectedin monotherapy in relapsed metastatic mesenchymal chondrosarcoma

Ghazal Tansir et al.

CLINICAL SARCOMA RESEARCH (2020)

添加到收藏夹

Article Education, Scientific Disciplines

Therapeutic development and current uses of BCL-2 inhibition

Andrew W. Roberts

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)

添加到收藏夹

Review Clinical Neurology

Mesenchymal Chondrosarcoma of the Brain with Metastasis: A Case Report with Literature Review

Sandeep Bhardwaj et al.

JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE (2020)

添加到收藏夹

Article Oncology

Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse

Liguo Zhang et al.

CANCER CELL (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting AKT for cancer therapy

Maryam Shariati et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)

添加到收藏夹

Article Oncology

Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS)

Javier Martin-Broto et al.

ONCOLOGIST (2019)

添加到收藏夹

Article Pathology

Minute mesenchymal chondrosarcoma within osteochondroma: an unexpected diagnosis confirmed by HEY1-NCOA2 fusion

Shunichi Toki et al.

HUMAN PATHOLOGY (2018)

添加到收藏夹

Review Oncology

Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology

Marc El Beaino et al.

CURRENT ONCOLOGY REPORTS (2018)

添加到收藏夹

Article Oncology

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

P. G. Casali et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells

Eun-Hui Jeong et al.

CELLULAR ONCOLOGY (2018)

添加到收藏夹

Review Medical Laboratory Technology

Extraskeletal Mesenchymal Chondrosarcoma

Komal Arora et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)

添加到收藏夹

Article Oncology

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Ahmet Zehir et al.

NATURE MEDICINE (2017)

添加到收藏夹

Article Oncology

Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)

Andres Redondo et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)

添加到收藏夹

Article Surgery

Primary Spinal Intradural Mesenchymal Chondrosarcoma with Several Local Regrowths Treated with Osteoplastic Laminotomies: A Case Report

Marek Derenda et al.

SURGERY JOURNAL (2017)

添加到收藏夹

Article Oncology

Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma

Hideo Morioka et al.

BMC CANCER (2016)

添加到收藏夹

Article Oncology

Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy

Nobuhito Araki et al.

EUROPEAN JOURNAL OF CANCER (2016)

添加到收藏夹

Article Oncology

Clinical Outcomes for Patients After Surgery and Radiation Therapy for Mesenchymal Chondrosarcomas

Karen De Amorim Bernstein et al.

JOURNAL OF SURGICAL ONCOLOGY (2016)

添加到收藏夹

Article Medicine, Research & Experimental

Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line

Yvonne de Jong et al.

LABORATORY INVESTIGATION (2016)

添加到收藏夹

Article Pathology

Evaluation of NKX2-2 expression in round cell sarcomas and other tumors with EWSR1 rearrangement: imperfect specificity for Ewing sarcoma

Yin P. Hung et al.

MODERN PATHOLOGY (2016)

添加到收藏夹

Article Oncology

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas

L. Paoluzzi et al.

CLINICAL SARCOMA RESEARCH (2016)

添加到收藏夹

Article Oncology

Mesenchymal chondrosarcoma: Prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study

Anna Maria Frezza et al.

EUROPEAN JOURNAL OF CANCER (2015)

添加到收藏夹

Article Oncology

Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study

Akira Kawai et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Central neurocytoma with ependymoma-like glial component

Fumi Kawakami et al.

BRAIN TUMOR PATHOLOGY (2015)

添加到收藏夹

Article Pathology

NY-ESO-1 (CTAG1B) expression in mesenchymal tumors

Makoto Endo et al.

MODERN PATHOLOGY (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Mesenchymal Chondrosarcoma of Bone and Soft Tissue: A Systematic Review of 107 Patients in the Past 20 Years

Jie Xu et al.

PLOS ONE (2015)

添加到收藏夹

Article Oncology

Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms

Anne-Laure Trepant et al.

TUMOR BIOLOGY (2015)

添加到收藏夹

Article Orthopedics

Radiation Therapy Is Associated With Fewer Recurrences in Mesenchymal Chondrosarcoma

Satoshi Kawaguchi et al.

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2014)

添加到收藏夹

Article Oncology

Chromosome aberrations and HEY1-NCOA2 fusion gene in a mesenchymal chondrosarcoma

Ioannis Panagopoulos et al.

ONCOLOGY REPORTS (2014)

添加到收藏夹

Article Pediatrics

Mesenchymal chondrosarcoma diagnosed on FISH for HEY1-NCOA2 fusion gene

Kunihiko Moriya et al.

PEDIATRICS INTERNATIONAL (2014)

添加到收藏夹

Article Pathology

Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl-2 Family Members and TGFβ as Potential Targets

Jolieke G. van Oosterwijk et al.

AMERICAN JOURNAL OF PATHOLOGY (2013)

添加到收藏夹

Article Oncology

GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study

A. Italiano et al.

ANNALS OF ONCOLOGY (2013)

添加到收藏夹

Article Clinical Neurology

Olig2-positive cells in glioneuronal tumors show both glial and neuronal characters: The implication of a common progenitor cell?

Nozomi Matsumura et al.

NEUROPATHOLOGY (2013)

添加到收藏夹

Article Cell Biology

The Insulin Receptor: Both a Prototypical and Atypical Receptor Tyrosine Kinase

Stevan R. Hubbard

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)

添加到收藏夹

Article Medical Laboratory Technology

Mesenchymal Chondrosarcoma Clinicopathologic Study of 20 Cases

Rachel J. Shakked et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2012)

添加到收藏夹

Article Oncology

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas

Axel Le Cesne et al.

EUROPEAN JOURNAL OF CANCER (2012)

添加到收藏夹

Article Oncology

Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data

Lu Wang et al.

GENES CHROMOSOMES & CANCER (2012)

添加到收藏夹

Article Oncology

Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma

Danielle Meijer et al.

GENES CHROMOSOMES & CANCER (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Whole-Transcriptome Sequencing Identifies Novel IRF2BP2-CDX1 Fusion Gene Brought about by Translocation t(1;5)(q42;q32) in Mesenchymal Chondrosarcoma

Kaja B. Nyquist et al.

PLOS ONE (2012)

添加到收藏夹

Article Pathology

Molecular Diagnosis in Ewing Family Tumors The Rizzoli Experience-222 Consecutive Cases in Four Years

Gabriella Gamberi et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2011)

添加到收藏夹

Article Clinical Neurology

Feasibility of Proton Beam Therapy for Chordoma and Chondrosarcoma of the Skull Base

Hiroshi Fuji et al.

SKULL BASE-AN INTERDISCIPLINARY APPROACH (2011)

添加到收藏夹

Article Anatomy & Morphology

FLI-1 Distinguishes Ewing Sarcoma From Small Cell Osteosarcoma and Mesenchymal Chondrosarcoma

Anna F. Lee et al.

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2011)

添加到收藏夹

Article Pathology

Immunoprofile of mesenchymal chondrosarcoma: aberrant desmin and EMA expression retention of INI1, and negative estrogen receptor in 22 female-predominant central nervous system and musculoskeletal cases

Julie C. Fanburg-Smith et al.

ANNALS OF DIAGNOSTIC PATHOLOGY (2010)

添加到收藏夹

Article Developmental Biology

FGF-receptor signalling controls neural cell diversity in the zebrafish hindbrain by regulating olig2 and sox9

Virginie Esain et al.

DEVELOPMENT (2010)

添加到收藏夹

Review Oncology

Cartilage tumours and bone development: molecular pathology and possible therapeutic targets

Judith V. M. G. Bovee et al.

NATURE REVIEWS CANCER (2010)

添加到收藏夹

Article Pathology

Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma

Sebastien Salas et al.

VIRCHOWS ARCHIV (2009)

添加到收藏夹

Article Oncology

Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults - Experiences of the CWS and COSS study groups

Tobias M. Dantonello et al.

CANCER (2008)

添加到收藏夹

Article Oncology

The clinical approach towards chondrosarcoma

Hans Gelderblom et al.

ONCOLOGIST (2008)

添加到收藏夹

Article Neurosciences

Management of primary spinal chondrosarcoma -: Report of two cases causing cord compression

DMS Prevedello et al.

ARQUIVOS DE NEURO-PSIQUIATRIA (2004)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Cdx1 homeodomain protein: an integrator of posterior signaling in the mouse

D Lohnes

BIOESSAYS (2003)

添加到收藏夹

Review Oncology

Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: chondrosarcoma and other cartilaginous neoplasms

AA Sandberg et al.

CANCER GENETICS AND CYTOGENETICS (2003)

添加到收藏夹

Review Cell Biology

HES and HERP families: Multiple effectors of the Notch signaling pathway

T Iso et al.

JOURNAL OF CELLULAR PHYSIOLOGY (2003)

添加到收藏夹

Article Pathology

Translocation der(13;21)(q10;q10) in skeletal and extraskeletal mesenchymal chondrosarcoma

S Naumann et al.

MODERN PATHOLOGY (2002)

添加到收藏夹

Article Anatomy & Morphology

Expression of transcription factors during oligodendroglial development

M Wegner

MICROSCOPY RESEARCH AND TECHNIQUE (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.